Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

249 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Incyte Announces Executive Leadership Appointments

By: Incyte via Business Wire

March 25, 2026 at 09:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Incyte (NASDAQ: INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans.

Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRAS^G12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive.

Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing late‑stage development programs across Hematology, Oncology and Immunology as well as Global Medical Affairs, a critical capability for data generation and reinforcing the Company’s scientific leadership throughout the healthcare community. A highly respected leader at Incyte for more than a decade, Dr. Stein’s scientific judgment, development expertise and patient-centric approach have been instrumental to the Company’s success.

Mohamed Issa, Pharm.D. has been appointed Executive Vice President and Head of U.S. Commercial. In this role, Mr. Issa will continue to oversee the U.S. Oncology business while assuming expanded responsibility for U.S. Immunology. These business units are being integrated into a single U.S. commercial organization to support strategic alignment and execution for new product launches, operational effectiveness and standardization of best practices. Mr. Issa is an experienced executive with a proven track record in new product launch planning and operations across both Oncology and Immunology, and his execution-oriented approach will be critical to sustain commercial performance at Incyte.

“These appointments reflect the significant contributions Pablo, Steven and Mohamed have made to Incyte and the value they continue to bring to the company,” said Bill Meury, Chief Executive Officer, Incyte. “Additionally, we are confident that integrating our U.S. commercial teams into one organization will drive effective launch execution and position Incyte for long-term success.”

As part of the transition, Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.

For more background on Incyte’s Leadership Team, please visit https://incyte.com/our-company/our-leadership.

About Incyte^®Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including any discussion of the strength of Incyte’s enterprise leadership and Incyte’s potential for future growth and long-term success.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, as detailed in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260325544544/en/

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	272.05	+3.79 (1.41%)
AAPL	276.83	-3.31 (-1.18%)
AMD	341.54	-19.00 (-5.27%)
BAC	52.19	-1.05 (-1.97%)
GOOG	379.64	-3.58 (-0.93%)
META	610.41	+1.66 (0.27%)
MSFT	413.62	-0.82 (-0.20%)
NVDA	198.48	+0.03 (0.02%)
ORCL	180.29	+8.46 (4.92%)
TSLA	392.51	+1.69 (0.43%)